INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a heterogenous disorder characterized by hyperglycemia, insulin resistance and beta cell insufficiency (1) . Pathological features of T2DM include increased endogenous glucose production, predominantly in the liver, and reduced glucose uptake into peripheral tissues, leading to impaired fasting and postprandial glycemic control (1, 2) . Poor diet and lack of exercise increase metabolic burden and drive weight gain, insulin resistance, dyslipidemia, and other features of the metabolic syndrome (3, 4) . Despite the development of new glucose-lowering therapies in the last decade, morbidity and mortality rates associated with T2DM have increased (5, 6) and the proportions of patients reaching desired glycemic targets have not changed (7) . In addition to stabilizing blood glucose levels, new therapies for T2DM should, therefore, aim to promote weight loss.
Glucagon-like peptide-1 (GLP-1) receptor agonists are established therapies for T2DM and provide effective glycemic control and modest weight loss (8) . Interestingly, pharmacodynamic effects of this drug class differ according to pharmacokinetic profiles. Short-acting GLP-1 receptor agonists (eg, lixisenatide) tend to promote more effective postprandial glucose reduction through delayed gastric emptying, whereas longer-acting agonists (eg, liraglutide or once-weekly preparations) have a more pronounced effect on fasting glucose, which is achieved via glucose-dependent insulin secretion and presumed glucagonostatic effects (8) (9) (10) .
It is believed that tachyphylaxis to the effects of long-acting GLP-1 receptor agonists on gastric emptying may, in part, explain some of these observed differences (8, 11) . Some studies in obese subjects, however, report that liraglutide 3.0 mg resulted in a delay in gastric emptying at 5 weeks that diminished by 16 weeks (12).
Glucagon receptor agonism may appear counterintuitive as a treatment modality for T2DM
given the known effect of glucagon in increasing hepatic glucose output (13) . However, (14, 15) , which could occur via upregulation of energy-expensive metabolic processes such as amino acid catabolism, ureagenesis and fatty acid oxidation. Glucagon can also promote a delay in gastric emptying time (GET) (16) , which may have favorable effects on postprandial glucose levels, and in certain conditions, glucagon is also an insulin secretagogue, potentiating insulin secretion (17, 18) .
In support of this, oxyntomodulin, an endogenous dual agonist for GLP-1 and glucagon receptors, is increased along with GLP-1 following bariatric surgery (19) , and is believed to contribute to weight loss and improved glucose control seen after bariatric surgery (20) . In addition, short-term treatment with oxyntomodulin in overweight or obese patients with or without T2DM significantly decreased body weight and elicited favorable gluco-regulatory effects (21, 22) . Peptides that combine an optimal ratio of GLP-1 and glucagon receptor agonism could, therefore, promote glucose-lowering activity and harness the beneficial effects of dual agonism on weight loss.
Cotadutide is a dual receptor agonist with balanced GLP-1 and glucagon activity that is under development for T2DM, obesity, and nonalcoholic steatohepatitis. Clinical and preclinical studies in T2DM have shown that cotadutide improves glycemic control and promotes body weight loss (23,24). In a randomized, controlled, phase 2a study, treatment with cotadutide resulted in a significant reduction in postprandial and fasting glucose levels, and body weight, compared with placebo in obese or overweight patients with T2DM (24). This randomized, placebo-controlled, double-blind, phase 2a study evaluated the efficacy and safety of different doses of cotadutide in overweight or obese patients with T2DM. Continuous glucose monitoring (CGM) was used to evaluate glycemic control in this study population. As an 
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Study design and procedures
In this randomized, placebo-controlled, double-blind, phase 2a study, 2 cohorts of overweight or obese patients with T2DM in 5 study sites in Germany received once-daily subcutaneous cotadutide (AstraZeneca, Gaithersburg, MD, USA) or placebo for 49 days on different titration schedules (Figures 1a and 1b) . In cohort 1, CGM sensors (Freestyle Libre ® Pro, Abbott Diabetes Care, Inc., Alameda, CA, USA) were applied 2 days prior to study-drug treatment and worn continuously through the end of the study (day 49). In cohort 2, serial measures of GET were undertaken throughout the study and at follow-up.
Patients
Eligible patients (aged ≥18 years) had T2DM and were all taking metformin monotherapy, with a glycated hemoglobin A1c (HbA1c) measurement of 48-69 mmol/mol (6.5-8.5%), and a body mass index of 27-40 kg/m 2 (inclusive). Patients receiving metformin monotherapy were eligible if no significant dose changes (increase or decrease ≥500 mg/day) occurred in the 3 months prior to screening. Patients receiving adjuncts to metformin (dipeptidyl peptidase-4 inhibitors, sulfonylureas, glinides, or sodium-glucose co-transporter-2 inhibitors) were allowed following a 4-week washout period. Patients were excluded if they had a medical condition that could interfere with the study, had acutely decompensated blood glucose control, or a history of type 1 diabetes mellitus or diabetic ketoacidosis. Patients were also excluded if they received oncedaily subcutaneous insulin within 90 days of screening, received an agent containing a GLP-1 analogue within the 30 days of screening or before 5 half-lives of the drug, or had received any investigational product as part of a clinical study. 
Randomization and masking
In cohort 1, patients were randomly assigned 2:1 to receive subcutaneous cotadutide or placebo equivalent at 50 μg for 7 days, followed by 100 μg for 7 days, then 200 μg for 7 days, and finally 300 μg for 28 days. In cohort 2, patients were randomly assigned 3:1 to receive subcutaneous cotadutide or placebo equivalent at 50 μg for 14 days, followed by 100 μg for 14 days, then 200 μg for 14 days, and finally 300 μg for 7 days. Randomization was performed using an interactive voice/web response system.
In both cohorts, patients were not given any dietary advice throughout the course of the study but were required to fast overnight for at least 10 hours prior to mixed-meal tolerance tests (MMTT). MMTTs were performed by administering 237 mL of Ensure Plus milkshake (350 calories) that comprised 51 g carbohydrates, 22 g sugars, 13 g protein, and 11 g fat (Abbott Laboratories, Columbus, OH). During the MMTT, plasma samples were taken at -15, 0, 15, 30, 60, 90, 120, 150, 180, and 240 minutes. All patients were followed-up for 28 days post-last treatment with the study drug. CGM sensor readings were double blinded during the study, and sensors were changed every 14 days. A 1-hour activation period and 12-hour warm-up period were factored into subsequent data analyses. All patients, investigators, and study-site personnel were blinded to study-drug treatment allocation.
Outcome Measures
The coprimary end points (assessed in cohort 1 only) were the percentage change from Exploratory end points assessed in cohort 2 included change from baseline to day 49 in glucose AUC0-4h post-MMTT, body weight, and HbA1c levels. GET was also assessed as an exploratory end point in cohort 2. GET was measured (as described previously (25)) following at least a 10hour fast using a 13 C-octanoate breath test in conjunction with a standardized egg meal with crackers at baseline, days 15, 29, 43, 50, and at follow-up (28 days post-last treatment). The nutritional content of the cracker and egg meal was 280 kcal: 11.1 g (16%) protein, 18.9 g (60%)
A c c e p t e d M a n u s c r i p t 11 fat, 16.1 g (23%) carbohydrates, and 0.9 g (1%) fiber. The meal contained 60 mL of water to dissolve the egg powder and was administered with another 250 mL of water.
Breath samples were centrally analyzed for 13 CO2 by y isotope-selective nondispersive infrared spectrometry (Analysen Technik, Bremen, Germany). GET was assessed 2.5 hours after administration of cotadutide or placebo on days 15, 29, and 43. No drug was administered prior to assessments at baseline, day 50, or follow-up. Glucose and insulin samples were drawn concurrently at baseline, day 50, and follow-up. GET was estimated using time for retention of 13 C to decline to 50% (GET t½) and time at which the percentage of 13 C dose excreted per unit time reached its peak (GET tlag). Metformin therapy was not washed out prior to GET assessments; other agents known to delay gastric emptying such as opiates, domperidone, and metoclopramide were excluded during the study. Post hoc analyses on the comparability of interstitial glucose measurements to plasma glucose measurements during MMTT were assessed.
The pharmacokinetics of cotadutide at 50 µg and 300 μg were assessed in cohorts 1 and 2.
Plasma concentrations of cotadutide were measured with liquid chromatography-mass spectrometry and used stable-isotope-labelled cotadutide for the internal standard (LGC group, Middlesex, UK). In cohort 1, samples for pharmacokinetic analyses were collected predose on Safety was assessed as a secondary end point in both cohorts. Treatment-emergent adverse events (TEAEs) were defined using the Medical Dictionary for Regulatory Activities (version 20.0 or higher) and elicited via subject self-report. The investigator determined whether the event was related to the study drug. Change from baseline over 7 days in the percentage of patients with nausea and vomiting was assessed as exploratory end points in both cohorts. In cohort 1, ambulatory blood pressure monitoring (ABPM) assessed changes from baseline in pulse rate, systolic blood pressure, and diastolic blood pressure on day 49 and at 28 days after last treatment (follow-up). 
Statistical analysis
A planned sample size of 39 patients for cohort 1 (cotadutide, n=26; placebo, n=13) provided 97% power to detect a change from baseline in glucose AUC of 28% (assuming standard deviation [SD]=20.0%) and 85% power to detect a change from baseline in body weight of 2.3% (assuming SD=2.2%) between treatment groups. For the prespecified analysis to detect a 12% change from baseline to day 7 in glucose AUC at the cotadutide 50 µg dose level with 80% power, it was determined that by pooling cohorts 1 and 2, the combined sample size for cotadutide (n=44) plus placebo (n=19) would enable benchmarking to prior studies (24). All statistical tests were 2-sided with a significance level set at 0.1. No adjustments for multiplicity were applied.
Efficacy analyses were performed in the intent-to-treat population (all patients who received ≥1 dose of the study drug and analyzed according to randomized treatment group). Safety analyses were performed in the as-treated population (all patients who received ≥1 dose of the study drug and analyzed according to study drug received). Pharmacokinetic analyses were performed in the pharmacokinetic population (defined as all participants who received ≥1 dose of cotadutide and had ≥1 pharmacokinetic sample taken that was above the lower limit of quantification).
For the coprimary end points and continuous secondary or exploratory efficacy end points, analysis of covariance (adjusted for treatment and measurement at baseline) was used. For proportion-related secondary or exploratory efficacy end points, a logistic regression with fixed effects of treatment and baseline measurement was used. Descriptive statistics were used to summarize safety data. ABPM measures were analyzed as summary measures (mean values) collected across a 24-hour period. Statistical analyses were performed using SAS ® System version 9.3 or higher (SAS Institute Inc., Cary, NC, USA). 
RESULTS
Between August 10, 2017 and February 8, 2018, 65 patients were randomized to receive either cotadutide (cohort 1, n=26; cohort 2, n=20) or placebo (cohort 1, n=13; cohort 2, n=6; Figure 2 ).
Patient demographics and baseline characteristics were generally well balanced between treatment groups in cohort 1; however, in cohort 2, patients receiving cotadutide had a numerically longer duration of T2DM compared with those receiving placebo ( Table 1) .
The coprimary end points were met. In cohort 1, significant reductions from baseline to day 49 were observed with cotadutide vs placebo in glucose AUC0- In cohorts 1 and 2, significant reductions from baseline to day 49 were observed with cotadutide vs placebo in fasting plasma glucose (both P < 0.001) and HbA1c levels (P < 0.001 and P = 0.037, respectively; Table 2 ). Pooled data from both cohorts revealed greater reductions in glucose AUC during MMTT with cotadutide 50 µg on day 7 vs placebo or baseline ( Table 2) . In both cohorts, a progressive and dose-dependent decrease in body weight over time was observed with cotadutide, with the greatest magnitude of weight loss observed in cohort 1 at 300 µg for 28 days. A greater proportion of patients achieved ≥5% decrease in body weight from baseline to day 50 with cotadutide vs placebo in cohort 1 (42% [11/26] In cohort 2, a dose-dependent delay in GET was observed with cotadutide vs placebo over time, with a lesser, but discernable, difference at day 50 and at follow-up (Figure 7) . A significant delay in GET t½ was observed with cotadutide vs placebo on day 43 (LS mean; 117.2 minutes vs -42.9 minutes; P = 0.0392; Table 3 ). A significantly prolonged GET tlag was observed with cotadutide vs placebo on day 43 (LS mean; 46.5 minutes vs -27.3 minutes; P = 0.0479]; Table   3 ). A numerical increase in GET t1/2 and GET tlag was seen at all dose levels; and GET tlag increased with exposure up to 200 µg. There was less of a delay in GET on day 50 at 300 µg with similar exposure; however, this was observed alongside a significant reduction in glucose AUC (-25.3%; 90% CI: -28.2, -22.4; P < 0.0001). Despite a marked reduction in glucose levels in cohort 2, insulin levels on day 50 were not statistically different with cotadutide vs placebo (Figure 8) . A delay in peak insulin level was also evident (Figure 8b) .
In cohort 1, a significant reduction from baseline to day 49 with cotadutide vs placebo was observed in alanine levels (LS mean [90% CI]: -60.5 μmol/L [-102.1, -18.9] vs 48.7 μmol/L [-11.5, 108.9]; P = 0.017; Table 4 ). Numerical reductions were observed in the levels of other amino acids, including cystine, glutamate, isoleucine, tryptophan, and tyrosine ( (Table 4 ). Additionally, in cohort 1, numerical reductions from baseline to day 49 in LDL cholesterol level and total cholesterol:HDL ratios, and significant reductions in triglyceride levels were observed with cotadutide vs placebo ( Table 4 ).
In cohort 1, significant changes from baseline to day 49 were observed with cotadutide vs In the cotadutide treatment group, TEAEs were reported in 85% (22/26) and 75% (15/20) of patients in cohorts 1 and 2, respectively ( Table 5) . No deaths or serious adverse events occurred during this study period. A TEAE ≥grade 3 of vomiting was reported in 1 subject treated with cotadutide in cohort 1 ( Table 5 ). Decreased appetite was the most common TEAE in cohort 1 with cotadutide (50% [13/26]; Table 5 ). The incidence of nausea and vomiting observed with cotadutide were 19% (5/26) and 12% (3/26), respectively, in cohort 1, and 35% (7/20) and 20% (4/20), respectively, in cohort 2 ( Table 5) . No TEAEs of clinically significant hypoglycemia were reported in either cohort 1 or 2. ABPM revealed a significant increase from baseline to day 49 in pulse rate with cotadutide vs placebo (P<0.001; Figure 10a ). No significant differences between treatment groups were observed for systolic or diastolic blood pressure (Figures 10b and 10c) . Repeat daily treatment with cotadutide at a dose range of 50 μg to 300 μg suggested linear pharmacokinetics for Cmax and AUC ( Table 6) . Cotadutide was associated with a tmax of 4-6 hours, and a t½ of approximately 8-9 hours at the tested doses ( Table 6) . absence of a delay in GET have been reported (8) . The profile for cotadutide demonstrates either a significant increase or unchanged postprandial insulin AUC and a delay in achieving peak insulin levels. This signature is presumably reflective of the combined effects of augmented insulin release and a delay in GET.
Given the known impact of glucagon on GET and the differential effects of short-and longacting GLP-1 analogues (9,10), it is unclear whether such effects are mediated via GLP-1 or glucagon receptor agonism. It is established that GLP-1 promotes a delay in GET via transmission of cholinergic and peptidergic inhibitory signals to the vagus nerve and tachyphylaxis is thought to arise through adaptation of the parasympathetic nervous system (11, 29) . The mechanisms of glucagon-mediated delay in GET are less well characterized; however, inhibition of gastrointestinal contractions have been recorded in response to glucagon (16) . Moreover, a direct effect on smooth muscle or sympathetic control have been proposed to mediate tonic effects in the gut (30). Tachyphylaxis to the effects of glucagon has also been reported (30). In addition to the observed tachyphylaxis, data from CGM demonstrate that postprandial glucose lowering occurs rapidly with cotadutide. This may be suggestive of an effect on the autonomic nervous system which could be due to either GLP1 or glucagon receptor agonism.
The magnitude of delay in GET observed with cotadutide was within the range observed for short-acting GLP-1 analogues (25). This suggests that there is no additive or synergistic effect A limitation to this study was that analysis of GET included missing data due to unrecordable delays in GET in several patients during the dosing phase. In addition, although 13 C octanoate is an accepted method for determining gastric emptying delay, criticisms of this methodology have been raised (31). Scintigraphy is the gold standard for assessing gastric emptying (32) but is not widely available due to limits on subject exposure to local radiation. The lack of washout of metformin may influence GET (33) and differences in the absorption and kinetics of glucose and octanoate could influence the interpretation of the results. Moreover, GLP-1 agonists have been found to affect small intestinal function (34), suggesting that cotadutide could also influence small intestinal absorption.
Cotadutide resulted in a significant reduction in the levels of the glucogenic amino acid alanine in comparison to placebo. This may provide evidence for glucagon receptor engagement given the known effects of glucagon in modulating amino acid levels. Although flux measurements were not undertaken in this study, this observation may imply that alanine is being consumed by gluconeogenesis, which is a predictable effect of glucagon receptor agonism associated with increased energy expenditure (35). However, cotadutide had pronounced effects in reducing fasting and overnight glucose levels. These observations are not indicative of an increase in hepatic glucose output under fasted conditions which would be expected if cotadutide promoted a net increase in gluconeogenesis and glycogenolysis. Moreover, there were no significant changes detected in fasting free-fatty acid levels or ketogenesis with cotadutide. The reason for this is unclear. It is, however, possible that concurrent increases in insulin masked the ability to Cotadutide was well tolerated at all dose levels. Extending the titration schedule to two weeks did not appear to improve tolerability. TEAEs in cohort 2 coincided with egg meals used for GET assessments, which may have led to the higher incidence of TEAEs in this cohort. A limitation of this study for evaluating tolerability was a lack of statistical power to draw inferences between the two cohorts and the absence of validated questionnaires. Larger studies are needed to further evaluate the tolerability of cotadutide at different titration schedules. 
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